CoChat

Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives

Open access
Ghiboub, Mohammed, Elfiky, Ahmed M. I., de Winther, Menno P. J., Harker, Nicola R., Tough, David F., de Jonge, Wouter J. · 2021 · Journal of Personalized Medicine

The DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.

Abstract

Histone deacetylases (HDACs) and bromodomain-containing proteins (BCPs) play a key role in chromatin remodeling. Based on their ability to regulate inducible gene expression in the context of inflammation and cancer, HDACs and BCPs have been the focus of drug discovery efforts, and numerous small-molecule inhibitors have been developed. However, dose-limiting toxicities of the first generation of inhibitors, which typically target multiple HDACs or BCPs, have limited translation to the clinic. Over the last decade, an increasing effort has been dedicated to designing class-, isoform-, or domain-specific HDAC or BCP inhibitors, as well as developing strategies for cell-specific targeted drug delivery. Selective inhibition of the epigenetic modulators is helping to elucidate the functions of individual epigenetic proteins and has the potential to yield better and safer therapeutic strategies. In accordance with this idea, several in vitro and in vivo studies have reported the ability of more selective HDAC/BCP inhibitors to recapitulate the beneficial effects of pan-inhibitors with less unwanted adverse events. In this review, we summarize the most recent advances with these strategies, discussing advantages and limitations of these approaches as well as some therapeutic perspectives, focusing on autoimmune and inflammatory diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jpm11050336

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 DNA methylation and histone modifications. Post-translational modifications of histones and DNA methylation provide a fine-tuned mechanism for regulating chromatin structure and dynamics. Panel (A) depicts methylation and acetylation of histone tails that involve the addition of methyl group (Me) and acetyl group (AC), respectively. These processes are catalyzed by the epigenetic writers histone methyltransferases (HMTs) and histone acetylases (HATs), respectively. DNA methylation is catalyzed by the epigenetic writers DNA methyltransferases (DNMTs), including DNMT1, DNMT3a, and DNMT3b, which add a methyl group on to the 5-carbon of the cytosine ring. Panel (B) illustrates examples of epigenetic readers that possess specialized domains that recognize specific covalent histone or DNA modifications and respond to upstream signals. Such crosstalk generates a different binding platform for the recruitment of other regulatory proteins, ultimately controlling the chromatin accessibility to transcription factors and gene transcription, such as plant homeodomain (PHD), WD40-repeat (WDR) proteins, and chromo domains that recognize histone methylation marks, broomodomian-containing protiens (BCPs) that recognize histone acetylation marks, and the methyl-CpG-binding proteins (MBPs) that recognize methylation of DNA. Panel (C) shows examples of epigenetic eraser proteins that can remove modifications from DNA or histones to regulate gene expression.
Figure 1 DNA methylation and histone modifications. Post-translational modifications of histones and DNA methylation provide a fine-tuned mechanism for regulating chromatin structure and dynamics. Panel (A) depicts methylation and acetylation of histone tails that involve the addition of methyl group (Me) and acetyl group (AC), respectively. These processes are catalyzed by the epigenetic writers histone methyltransferases (HMTs) and histone acetylases (HATs), respectively. DNA methylation is catalyzed by the epigenetic writers DNA methyltransferases (DNMTs), including DNMT1, DNMT3a, and DNMT3b, which add a methyl group on to the 5-carbon of the cytosine ring. Panel (B) illustrates examples of epigenetic readers that possess specialized domains that recognize specific covalent histone or DNA modifications and respond to upstream signals. Such crosstalk generates a different binding platform for the recruitment of other regulatory proteins, ultimately controlling the chromatin accessibility to transcription factors and gene transcription, such as plant homeodomain (PHD), WD40-repeat (WDR) proteins, and chromo domains that recognize histone methylation marks, broomodomian-containing protiens (BCPs) that recognize histone acetylation marks, and the methyl-CpG-binding proteins (MBPs) that recognize methylation of DNA. Panel (C) shows examples of epigenetic eraser proteins that can remove modifications from DNA or histones to regulate gene expression.CC BY · PubMed Central
Figure 2 Possible mechanism for inhibition of inflammatory gene expression by HDACi. (A) In steady state, there is an equilibrium between acetylation (AC) and deacetylation, which maintains a pool of epigenetic readers available for recruitment to newly induced promoters, recruitment of transcription factors (TF), and induction of gene expression. (B) Histone deacetylase (HDACs) inhibition increases acetylation of histones that sequester the epigenetic readers, such the bromodomain-containing proteins (BCPs), preventing their recruitment to newly induced promoters.
Figure 2 Possible mechanism for inhibition of inflammatory gene expression by HDACi. (A) In steady state, there is an equilibrium between acetylation (AC) and deacetylation, which maintains a pool of epigenetic readers available for recruitment to newly induced promoters, recruitment of transcription factors (TF), and induction of gene expression. (B) Histone deacetylase (HDACs) inhibition increases acetylation of histones that sequester the epigenetic readers, such the bromodomain-containing proteins (BCPs), preventing their recruitment to newly induced promoters.CC BY · PubMed Central
Figure 3 Selective targeting of myeloid cells with HDACi. CES-1 expression in humans is restricted to hepatocytes and cells of the mononuclear myeloid lineage, such as monocytes and macrophages. (A) When ESM-HDACi enters into CES-1-negative cells such as T and B cells, the compound freely diffuses out of the cells; lack of retention of the HDACi minimizes the pharmacological effect. (B) After entry of ESM-HDACi into CES-1-positive cells ①, esters are selectively hydrolyzed by the CES-1 enzyme ②, generating charged acids ③ that are less able to cross the membrane. This leads to intracellular retention of HDACi ④ and enhanced pharmacological effect (e.g., histone hyperacetylation and repression of proinflammatory genes) ⑤.
Figure 3 Selective targeting of myeloid cells with HDACi. CES-1 expression in humans is restricted to hepatocytes and cells of the mononuclear myeloid lineage, such as monocytes and macrophages. (A) When ESM-HDACi enters into CES-1-negative cells such as T and B cells, the compound freely diffuses out of the cells; lack of retention of the HDACi minimizes the pharmacological effect. (B) After entry of ESM-HDACi into CES-1-positive cells ①, esters are selectively hydrolyzed by the CES-1 enzyme ②, generating charged acids ③ that are less able to cross the membrane. This leads to intracellular retention of HDACi ④ and enhanced pharmacological effect (e.g., histone hyperacetylation and repression of proinflammatory genes) ⑤.CC BY · PubMed Central
Figure 4 Phylogenetic tree of the human bromodomain-containing protein subgroups. On the basis of sequence homology, BCPs are classified into eight different subgroups (families). The distinct families are indicated by Roman numbers (I–VIII) in circles and illustrated with different colors.
Figure 4 Phylogenetic tree of the human bromodomain-containing protein subgroups. On the basis of sequence homology, BCPs are classified into eight different subgroups (families). The distinct families are indicated by Roman numbers (I–VIII) in circles and illustrated with different colors.CC BY · PubMed Central
Figure 5 Selective domain targeting of BD1 and BD2. (A) BET proteins family of BCPs comprise the ubiquitously expressed BRD2, BRD3, and BRD4 and BRDT, which all harbor two highly conserved tandem bromodomains, BD1 and BD2, allowing them to recognize acetylated lysine. (B) BD1 and BD2 have distinct functions. BD1 binding is sufficient to maintain homeostatic and oncogenic gene transcription programs, while BD2 binding is required to promote an inflammatory transcriptional response. (C) Domain-selective inhibitors for BD1 and BD2 show preferential effects on different types of cellular functions [141].
Figure 5 Selective domain targeting of BD1 and BD2. (A) BET proteins family of BCPs comprise the ubiquitously expressed BRD2, BRD3, and BRD4 and BRDT, which all harbor two highly conserved tandem bromodomains, BD1 and BD2, allowing them to recognize acetylated lysine. (B) BD1 and BD2 have distinct functions. BD1 binding is sufficient to maintain homeostatic and oncogenic gene transcription programs, while BD2 binding is required to promote an inflammatory transcriptional response. (C) Domain-selective inhibitors for BD1 and BD2 show preferential effects on different types of cellular functions [141].CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

See all 31

Metadata

Authors
Ghiboub, M., Elfiky, A. M. I., de Winther, M. P. J., Harker, N. R., Tough, D. F., & de Jonge, W. J.
Affiliations
  • GlaxoSmithKline (United Kingdom) (GB)
  • Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
  • Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centers, University of Amsterdam, 1105 BK Amsterdam, The Netherlands
Venue
Journal of Personalized Medicine
Publisher
MDPI AG
Published
2021-04-23
Volume
11
Issue
5
Pages
336
ISSN
2075-4426 (ISSN-L)
OpenAlex
W3159535985
Cited by
28
References
161
Citations by year
2026: 6 · 2025: 4 · 2024: 5 · 2023: 7 · 2022: 4 · 2021: 2
FWCI
0.47
Type
journal article
Language
en
Open access
Locations
  • Journal of Personalized Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
European Commission (HORIZON2020, 641665)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords
histone deacetylase, epigenetic reader protein, selective inhibitors, isoform-selective inhibitors, chromatin remodeling, autoimmune disease, inflammatory diseases, histone deacetylase inhibitors, bromodomain inhibitors, drug toxicity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.